Specific Systems of Treatment
Story. Obtainable in packages at some health-food stores, the herbal mixture lists “Red clover, spe- cial spice, Indian sage.” As you can see, part of the formula remains a secret.
For some unknown reason, a number of years ago the Jason Winters formula had red clover, chaparral, cayenne, and “spices (undisclosed).” The new name, “Indian sage,” is very likely a po- etic name for chaparral, possibly to hide its iden- tity.
The present writer would think that, if an herbal mixture alone were to be desired, Essiac would have a far better track record, with decades of documented cases.
____________________ E.S. SIRIS, M.D., 1980
As of the mid-1990s, over 30 research and clinical studies of clodronate had been made. Here is the results of one of them:
Twenty-seven patients with malignant bone disease (hypercalcemia) were given intravenous in- jections of clodronate. Within two days, serum cal- cium levels had significantly decreased, By the fourth day, 89% (24 patients) had reached normal calcium levels.
No other chemical compounds (including cal- citonin, glucocorticoids, mithramycin, and pros- taglandin synthetase inhibitors) accomplish what clodronate can do in treating bone cancer.
Bone cancer generally begins as the result of metastasis. Cancer somewhere else (breast, prostate, etc.), when it begins to spread, may en- ter the bones. More than 80% of advanced pros- tate cancer metastasis spreads to the bones.
Note to researchers: Close attention should be paid the structure of clodronate and its use, in preventing as well as elimi- nating bone cancer. Additional serious studies are needed here.
Working Summary: In clodronate, we have a chemical that is not natural to the body. Yet it has only minor side effects. It can be purchased by mail.
Clodronate is produced under the trade name of Bonefos by the Leiras Corporation, in Finland. It is approved for use in 25 countries, but not in the U.S. But Americans can order a three-month supply by mail.
Dr. Siris is one of the pioneers in working with clodronate in the treatment of certain forms of can- cer.
Clodronate is a member of a group of chemi- cals called the bisphosphonates. They are struc- turally similar to the pyrophosphates which oc- cur naturally in the bones and body fluids (plasma, urine, and saliva). It is the task of pyrophosphates to regulate calcium balance. This involves build- ing new bone and reabsorbing old bone.
Side effects tend to be mild, short duration, and easy to manage. They include nausea, vomit- ing, and diarrhea. Lowering the dosage generally solves the problem. Three cases of kidney failure have been reported.
The dosage is as follows: A single daily intravenous infusion of 300 mg (1 ampule), for three to five days (but some- times ten days). This generally returns the cal- cium level to normal.
The bisphosphonates can also regulate calcium and bone development. But, because of the car- bon atom in their molecules, they are very versa- tile. Of them, clodronate, with its two chlorine at- oms attached to the carbon atom, has the highest biological activity of any bisphosphonate.
Clodronate is given to treat bone cancer. Because clodronate attaches itself to calcium, it is able to stop the osteoclasitc activity of bone resorption. Bone cancer is an excess resorption (elimination) of bone tissue, and clodronate stops this wasting away and normalizes calcium and bone levels.
Thereafter, the patient can be maintained with oral clodronate. This is 1,600 mg to 2,400 mg daily, in two or three equal doses. (In ad- vanced cases, the initial dose may be 3,200 mg daily.)
Sometimes treatment of mild cases are be- gun with oral doses, with no preliminary injec- tions. The initial dose is 3,200 mg daily, which is reduced as the calcium level improves. From that time onward, the maintenance dose of 1,200 mg daily is generally adequate. (This translates to one 400-mg capsule taken 30 min- utes before each of the three meals.)
Radiation can reduce the pain of bone cancer, but it does not stop the disease. Chemotherapy does not work either. But clodronate has been found to be very useful.
Since this substance binds with calcium, it must not be taken with calcium-containing foods or liquids. For this reason, it is always given 30 minutes before the meal begins.
Clodronate normalizes the level of calcium in the blood, prevents hypercalcemia, stops the spread (metastasis) of cancer to new areas, and retards or reverses the growth of existing me- tastases. It also reduces bone pain and the like- lihood of fractures.
If, bone scans reveal that there is sufficient im- provement, the dosage can be reduced to two 400- mg capsules twice a day. After six to nine months, it may be possible to reduce this to one 400-mg capsule daily.
The taking of clodronate must not be termi-